SEC Form 4 filed by Kirske David

$CTIC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CTIC alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
KIRSKE DAVID

(Last) (First) (Middle)
3101 WESTERN AVENUE, SUITE 800

(Street)
SEATTLE WA 98121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CTI BIOPHARMA CORP [ CTIC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication

  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/26/2023 U 17,547(1)(2) D $9.1 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.25 06/26/2023 D 25,000 (3) (3) Common Stock 25,000 (3) 0 D
Stock Option (Right to Buy) $3.19 06/26/2023 D 315,000 (3) (3) Common Stock 315,000 (3) 0 D
Stock Option (Right to Buy) $4.14 06/26/2023 D 83,396 (3) (3) Common Stock 83,396 (3) 0 D
Stock Option (Right to Buy) $0.9489 06/26/2023 D 270,216 (3) (3) Common Stock 270,216 (3) 0 D
Stock Option (Right to Buy) $1 06/26/2023 D 340,000 (3) (3) Common Stock 340,000 (3) 0 D
Stock Option (Right to Buy) $3.3 06/26/2023 D 150,000 (3) (3) Common Stock 150,000 (3) 0 D
Stock Option (Right to Buy) $4.49 06/26/2023 D 280,000 (3) (3) Common Stock 280,000 (3) 0 D
Stock Option (Right to Buy) $4.55 06/26/2023 D 200,000 (3) (3) Common Stock 200,000 (3) 0 D
Explanation of Responses:
1. Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.
2. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
3. Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Remarks:
/s/ Adam R. Craig, attorney-in-fact for David Kirske 06/26/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CTIC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTIC

DatePrice TargetRatingAnalyst
10/17/2022$13.00Outperform
SVB Leerink
9/1/2022$13.00Buy
Jefferies
7/7/2022$10.00Outperform
Cowen
3/2/2022$4.00 → $5.00Market Outperform
JMP Securities
3/2/2022$5.00 → $8.00Buy
Needham
12/1/2021$6.00 → $5.00Buy
Needham
8/9/2021$7.00Buy
BTIG Research
More analyst ratings

$CTIC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. STOCKHOLM, June 24, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra), successfully completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (NASDAQ:CTIC) (CTI), at a price of USD 9.10 per sh

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

    SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of M

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sobi to Acquire CTI BioPharma

    Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTIC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CTIC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CTIC
SEC Filings

See more

$CTIC
Leadership Updates

Live Leadership Updates

See more
  • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

    FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

    $CALT
    $CELU
    $CTIC
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

    SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a po

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTIC
Financials

Live finance-specific insights

See more
  • Sobi to Acquire CTI BioPharma

    Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

    SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

    – Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo

    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTIC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more